Treatment Options in EGFR-Mutant NSCLC in Second Line and Be

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

Related Keywords

Joshuak Sabari , , Evolving Treatment Paradigm , Advanced Non , Small Cell Lung Cancer , Second Line , Non Small Cell Lung Cancer , Nsclc , Advanced Non Small Cell Lung Cancer , Advanced Nsclc , Nsclc Treatment , Egfr Mutant Lung Cancer , Egfr Mutated Lung Cancer , Second Line Treatment , Mariposa 2 ,